Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well beyond glucose.
Link as first comment.
@longevitytech.bsky.social
@longevitytech.bsky.socialAscensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well beyond glucose.
Link as first comment.
London-based Sava Technologies raised $36 million in Series B from Ascensia Diabetes Care to commercialize its subcutaneous glucose sensor. A European launch is scheduled for 18 to 24 months after obtaining CE approval.